Ente Ospedaliero Cantonale

Their core work

Ente Ospedaliero Cantonale (EOC) is the public hospital network of Canton Ticino in southern Switzerland, operating multiple hospitals and clinical research units. Within H2020, EOC contributes clinical and biomedical expertise to projects focused on drug discovery, precision medicine, and extracellular vesicle-based therapies. Their research involvement centers on translating hospital-based clinical knowledge into advanced in vitro modeling, liquid biopsy diagnostics, and cell-free therapeutic approaches. As a public healthcare institution, they bring real-world patient data context and clinical validation capacity to European research consortia.

What they specialise in

How they've shifted over time

EOC's H2020 trajectory shows a clear shift from social care toward advanced biomedical research. Their earliest project (DREAM, 2016) addressed wellbeing and independent living with minimal funding, suggesting an exploratory entry into EU research. From 2019 onward, they pivoted sharply into high-value biomedical work — first drug discovery and in vitro modeling (SINERGIA), then extracellular vesicle therapeutics (MARVEL) — with substantially larger budgets reflecting deeper scientific engagement.

EOC is moving toward translational biomedical research, particularly in precision medicine platforms and cell-free therapies, suggesting growing ambition to bridge clinical practice with advanced biological technologies.

How they like to work

EOC participates exclusively as a consortium partner, never as coordinator, which is typical for a clinical institution contributing domain expertise rather than driving project management. Across just 3 projects they have worked with 22 unique partners in 13 countries, indicating they join broad, internationally diverse consortia. Their funding scheme mix (MSCA-RISE, MSCA-ITN, RIA) suggests they value researcher mobility and training networks alongside technical research — likely offering clinical placements and knowledge exchange.

Despite only 3 projects, EOC has built connections with 22 partners across 13 countries, reflecting participation in large multi-national consortia. Their network spans widely across Europe with no obvious geographic concentration beyond their Swiss base.

What sets them apart

EOC offers something uncommon in EU consortia: a public hospital system in Switzerland's Italian-speaking canton that actively engages in translational biomedical research. Unlike pure research institutes, they can connect bench science (exosome capture, bioprinting, microfluidics) with clinical reality — patient cohorts, diagnostic workflows, and therapeutic validation. For consortium builders, partnering with EOC means gaining a clinical anchor in Switzerland with direct access to hospital infrastructure and patient-facing expertise.

Highlights from their portfolio

• SINERGIA
  Largest project by funding (EUR 562K) combining microfluidics, bioprinting, and drug screening into an integrated precision medicine platform.
• MARVEL
  Addresses the commercially promising field of extracellular vesicle manufacturing with direct therapeutic applications in cardiac repair and cancer diagnostics.